Welcome to our dedicated page for Modular Medical news (Ticker: MODD), a resource for investors and traders seeking the latest updates and insights on Modular Medical stock.
Modular Medical Inc., based in Beacon House Orchard Farm Ivinghoe Aston, Buckinghamshire, United Kingdom, is a development-stage medical device company focused on designing, developing, and commercializing an insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Their products target both type 1 and rapidly growing type 2 diabetes markets, especially in terms of device adoption.
The latest news from Modular Medical Inc. announced their commencement of an underwritten public offering of shares of its common stock to fund operations and maintain working capital. Titan Partners Group, a division of American Capital Partners, is the sole book-running manager for the offering. The company intends to utilize the net proceeds from the offering for capital expenditures and general corporate purposes.
Modular Medical's mission is to provide top-quality insulin delivery that is both affordable and easy to learn, extending glycemic control access to a wider audience. The company's founder, Paul DiPerna, is a seasoned medical device professional with a background in microfluidics engineering and an innovative history in the diabetes market, previously founding Tandem Diabetes and its t:slim insulin pump.
Modular Medical Inc. (NASDAQ: MODD) announced its presentation at Oppenheimer's 32nd Annual Healthcare Conference on March 15, 2022. CEO Jeb Besser will represent the company in a virtual session starting at 8:40 am Eastern Time. A webcast of the presentation will be accessible at modular-medical.com/events and archived for 30 days. Modular Medical aims to launch innovative insulin pump technology, improving ease of use and affordability for diabetes management.
Modular Medical has appointed James "Jeb" Besser as its new CEO, effective immediately. Besser, with 25 years of experience in life sciences and technology, previously served as managing member of Manchester Management LLC, the company’s largest shareholder. Lynn Vos, the outgoing CEO since August 2021, remains on the board and will assist in marketing strategies. The company also reaffirmed its timeline for the 510(k) submission of its next-generation MODD1 insulin pump to the FDA, expected in Q2 2022, aiming to improve access to insulin delivery technology.
Modular Medical, Inc. (NASDAQ:MODD) has priced its underwritten public offering of 2,500,000 units at $6.00 each, with expected gross proceeds of $15 million. Each unit comprises one share and one warrant. The proceeds will fund corporate purposes, sales infrastructure, R&D, production capabilities, and repayment of a promissory note. The company’s common stock is now approved for listing on the Nasdaq Capital Market starting February 10, 2022. The offering is set to close on February 14, 2022.
Modular Medical, Inc. (OTCQB:MODD) has expanded its Board of Directors by appointing Steven G. Felsher and Philip B. Sheibley as independent directors. CEO Lynn O'Connor Vos highlighted their extensive experience, which will be invaluable as the company aims to enhance insulin pump technology for better diabetes care, particularly for underserved communities. Felsher brings over 30 years of financial and management expertise, while Sheibley focuses on life sciences consulting, further strengthening the company's leadership as it prepares for product commercialization.
Modular Medical, Inc. (OTCQB:MODD) announced a 1-for-3 reverse stock split effective November 29, 2021, aimed at meeting the Nasdaq Capital Market listing requirements, specifically a minimum stock price of $4.00. The company’s common stock will initially trade as MODDD before reverting to MODD after 20 business days. The reverse split consolidates shares, ensuring no fractional shares are issued. Modular Medical is committed to providing innovative insulin delivery solutions for diabetes management. There are no assurances on meeting all Nasdaq requirements or securing uplisting approval.
Modular Medical has appointed Lynn O'Connor Vos as the new CEO, effective immediately, while founder Paul DiPerna transitions to Chairman and Chief Technology Officer. O'Connor Vos aims to enhance the company's insulin delivery system, targeting accessibility for the 3.5 million Americans needing intensive insulin therapy. With a background in healthcare leadership, she plans to pursue public-private partnerships and refine patient experiences. The company emphasizes affordable insulin pump technology for broader adoption, particularly in underserved communities.
Modular Medical, Inc. (OTCQB:MODD) announced the appointment of Lynn O'Connor Vos to its board of directors, bringing extensive healthcare expertise. Vos, a former CEO of Greyhealth Group, has a proven track record of driving revenue growth and establishing partnerships in the healthcare sector. Her leadership at the Muscular Dystrophy Association saw a significant organizational turnaround. CEO Paul DiPerna expressed confidence that Vos's insights will enhance Modular's market presence and commitment to improving diabetes care.
Modular Medical, Inc. (OTCQB:MODD) announced a private placement of $6.6 million in convertible promissory notes to advance its insulin delivery technology.
The funds will be used for software and firmware development for the MODD Pivot™ product and necessary third-party testing for a 510k submission to the FDA in 2021. The notes carry a 12% annual interest rate and will convert into common stock upon a future financing exceeding $12 million. Over 50% of the financing came from existing investors, highlighting strong support for the company's mission.
Modular Medical, Inc. (OTCQB: MODD) announced the formation of a multi-disciplinary Advisory Board to enhance its insulin delivery technology. This Board, composed of renowned health care professionals, will collaborate with leadership to boost development and commercialization efforts. CEO Paul DiPerna emphasized the Board's diverse expertise as vital for reflecting real-world patient care issues. The Board aims to address the accessibility and usability of insulin pumps, making them simpler and more affordable for diabetes patients.
Modular Medical, Inc. (OTCQB:MODD) announced the relocation to a new 7,300 square foot headquarters in San Diego, CA, enhancing R&D capabilities for insulin pump development. The facility features a clean-room manufacturing environment and environmentally controlled test labs, crucial for upcoming 510(k) submission and increased testing activity. With a current staff of 20 and plans to hire for key positions, Modular Medical aims to expand access to advanced diabetes technology for underserved markets. CEO Paul DiPerna emphasized the strategic timing of this move amidst ongoing technology validation.
FAQ
What is the current stock price of Modular Medical (MODD)?
What is the market cap of Modular Medical (MODD)?
What is Modular Medical Inc.'s primary focus?
Who is the founder of Modular Medical Inc.?
What recent event did Modular Medical Inc. announce?
Who is managing the underwritten public offering for Modular Medical Inc.?
What is Modular Medical Inc.'s mission?
What are the markets targeted by Modular Medical Inc.'s products?
What are the intended uses of the net proceeds from the public offering?
What is the geographical location of Modular Medical Inc.?
What is the background of Steve Gemmell, the newly appointed Vice President of Engineering at Modular Medical Inc.?
What milestone did Modular Medical Inc. achieve recently?
